NPPB and pulmonary arterial hypertension: Our analyses of secondary endpoints confirmed that PAH treatment provides statistically significant benefits vs placebo on functional parameters (6MWD, Borg dyspnea index) and cardiac biomarkers (NT-proBNP) in the overall PAH cohort.